AFYX Therapeutics
Copenhagen
About AFYX Therapeutics
AFYX Therapeutics is changing the way mucosal diseases are treated. They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. Their proprietary Rivelin® patch is flexible, biodegradable, and adhesive to mucosal surfaces. Designed with electrospinning technology, it delivers a therapeutic directly to the site in need, without interfering with patients’ daily activities.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $30.7M
- Funding stage: Early Stage Venture
- Last round: Debt Financing (Jun 2019)
- Website: afyxtx.com
- Phone: [email protected]@afyxtx.com
Industries & Categories
Biotechnology, Clinical Trials, Delivery, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/afyx-therapeutics-85747 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.